scholarly journals Suboptimal concordance in testing and retesting results of triple-negative breast carcinoma cases among laboratories: one institution experience

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Jose De Jesus ◽  
Marilin Rosa
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Breast Carcinoma ◽  
Triple Negative ◽  
Treatment Plan ◽  
Growth Factor Receptor ◽  
Predictive Testing ◽  
Patient History ◽  
Triple Negative Breast Carcinoma ◽  
Epidermal Growth

Abstract Background Triple-negative breast carcinoma (TNBC) patients do not benefit from hormone- or human epidermal growth factor receptor 2- (HER2-) targeted therapies. Accurate testing is pivotal for these patients. Methods TNBC cases that were retested at our institution during a 3-year period were evaluated for concordance rates in estrogen (ER) and progesterone (PR) receptor and HER2 results. Results We found 19 (22%) discrepancies (13 major/6 minor) among 86 cases. Minor discrepancies were in HER2 changes by immunohistochemistry, and all cases were demonstrated to be negative by and dual in situ hybridization. All major discrepancies were in ER/PR expression changes. In only 2 cases the treatment changed based on repeated results and/or patient history. Conclusions Discrepancies in prognostic/predictive testing continue to be frequent despite rigorous regulations. However, since for the majority of patients in our setting, the treatment plan did not change, reflex retesting for TNBC has been deemed unnecessary in our institution.

scholarly journals Immunohistoochemical evaluation of GATA-3, pAKT and Ki-67 in triple negative breast carcinoma

2017 ◽  
Vol 7 (2) ◽  
pp. 1196-1201
Author(s):  
Gopi Aryal ◽  
Sameer Chhetri Aryal ◽  
Yurie Soejima ◽  
Victoria Sheckler ◽  
Yoshinobu Eishi ◽  
...  
Keyword(s):  
Triple Negative ◽  
Ductal Carcinoma ◽  
Growth Factor Receptor ◽  
Breast Cancers ◽  
Breast Carcinomas ◽  
Ki 67 ◽  
Triple Negative Breast Carcinoma ◽  
Epidermal Growth ◽  
Japanese Guidelines

Background: Triple-negative breast cancers lack expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor -2. These tumors have been known to be clinically aggressive. We evaluate GATA-3, pAKT and Ki-67 expression in 35 triple negative breast carcinomas.Materials and Methods: A total of 35 triple negative breast carcinomas were included in this study. The histological subtyping was done according to Japanese guidelines for breast cancer.Results: GATA-3 was positive in 60% (21/35) of tumors. High GATA-3 expression was observed in ductal carcinoma in situ.  pAKT expression was demonstrated in 85.7 % (30/35) of TNBCs. The levels of expression of GATA-3 and pAKT showed no significant association with nuclear grading. (P=0.761 and P=0.487, respectively). Ki-67 labeling index was positively correlated with nuclear grading (p<0.001).Conclusion: GATA-3 expression has no relation with ER and PR expression and pAKT and GATA-3 are strongly expressed in TNBCs. 

scholarly journals High Intrinsic Expression of P-glycoprotein and Breast Cancer Resistance Protein in Canine Mammary Carcinomas Regardless of Immunophenotype and Outcome

Animals ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 658
Author(s):  
Michela Levi ◽  
Luisa Vera Muscatello ◽  
Barbara Brunetti ◽  
Cinzia Benazzi ◽  
Federico Parenti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Breast Cancer Resistance Protein ◽  
Triple Negative ◽  
Growth Factor Receptor ◽  
Cancer Resistance ◽  
P Glycoprotein ◽  
Epidermal Growth ◽  
Resistance Protein

P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are major actors in multidrug resistance (MDR) phenomenon in both human and canine mammary carcinomas (CMCs). The aim of this study was to investigate an association between the intrinsic expression of P-gp and BCRP compared to the immunophenotypes and outcome in CMCs. Fifty CMCs were evaluated at immunohistochemistry (IHC) for P-gp, BCRP, Estrogen receptor alpha (ER), Progesterone receptors (PR), Human Epidermal Growth Factor Receptor type 2 (HER2), basal cytokeratins 5/6 (CK5/6), Epidermal Growth Factor Receptor 1 (EGFR), and Ki67 proliferation index. P-gp and BCRP positive cases were, respectively, 52% and 74.5%, with a significantly higher expression of BCRP than P-gp. Five immunophenotypes were defined in 37 out of 50 CMCs: 9 (24.3%) Luminal A, 5 (13.5%) Luminal B, 9 (24.3%) HER2 overexpressing, 9 (24.3%) Triple-negative basal-like, and 5 (13.5%) Triple-negative non-basal-like. In all CMCs at least one marker was expressed. Follow-up data were available for 25 animals. The average cancer-specific survival was 739 ± 444 days. A number of CMCs bear a high expression of P-gp and BCRP but no significant association was found between their expression and the immunophenotypes, Ki67 index, the histological grade, and tumor-related death.

Sign in / Sign up

Export Citation Format

Share Document